2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
Paolo A. Ascierto, Francesco M. Marincola
EBioMedicine · 2015
doi:10.1016/j.ebiom.2015.01.011 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The history of clinical oncology has witnessed several revolutionary therapeutic advances that have significantly improved cancer care. These have included the introduction of cisplatin in the 1970s for testicular and ovarian cancers, the taxanes in the 1990s for breast and other solid tumors, targeted therapy with anti-HER2 for breast cancer and c-Kit inhibitors for chronic myeloid leukemia and other cancers at the start of this millennium. Each of these treatments has revolutionized outcomes for patients with various types of cancer.
Abstract licence: CC BY-NC
References13
13 more references, whose wording the paper’s licence keeps private.
Cited by papers we hold2
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.